Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
US12227583B2 · kind B2 · utility
0Cited by
8References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2019 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | May 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.